Conference item icon

Conference item

SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component

Abstract:
The anti-retroviral agent, nelfinavir, demonstrates radiosensitising effects in pre-clinical models of pancreatic cancer. The primary objective of Stage 1 was to establish the maximum tolerated dose (MTD) of nelfinavir combined with capecitabine-chemoradiation (CRT) after gemcitabine+nab-paclitaxel (GEMABX) induction chemotherapy. Other outcomes included overall survival and progression-free survival.
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS; CSM
ORCID:
0000-0002-3006-8730
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Bridgewater, J More by this author
Radhakrishna, G More by this author
Expand authors...
Publisher:
National Cancer Research Institute Publisher's website
Publication date:
2018-11-06
Acceptance date:
2018-06-25
Pubs id:
pubs:859286
URN:
uri:afea16de-e50c-4b7a-933f-aa18ac088ee3
UUID:
uuid:afea16de-e50c-4b7a-933f-aa18ac088ee3
Local pid:
pubs:859286

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP